newsfilter
← Latest News
GlobeNewswire·

Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates

-- Patient Enrollment Completed in both Phase 2 OraGrowtH Trials ---- Primary Outcome Data for both OraGrowtH Trials Expected 4Q 2023 ---- Interim Data from OraGrowtH Trials Accepted for Presentation at PES 2023 –--